

May 27, 2022

Honorable Nancy Skinner, Chair
Joint Legislative Budget Committee
Senate Budget and Fiscal Review Committee

Honorable Phil Ting, Chair
Assembly Budget Committee

Honorable Anthony Portantino, Chair
Senate Appropriations Committee

Honorable Chris R. Holden, Chair
Assembly Appropriations Committee

Section 28.00—Department of Public Health, Fiscal Year 2021-22 Budget Adjustment

Pursuant to the provisions of Section 28.00, 2021 Budget Act, the following report is respectfully submitted.

The Department of Finance has received the attached Section 28.00 application from the Department of Public Health (DPH) for the purpose of increasing expenditure authority in Item 4265-001-0001 by \$17,877,000 for Program 4045—Public and Environmental Health and in Item 4265-111-0001 by \$1,710,000 for Program 4045—Public and Environmental Health. This increase is needed to expend an Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) grant provided by the United States Department of Health and Human Services to implement and support genome sequencing activities. ELC grant funds are managed by Heluna Health, and DPH has a reimbursement contract with Heluna Health to expend the grant funds.

DPH received official notification of the availability of additional, unanticipated funds on May 12, 2021 but did not notify Finance within 45 days of this date due to increased workload pressures and redirection of staff resources toward COVID-19 pandemic response.

Notification was previously sent to the Joint Legislative Budget Committee on December 21, 2021; however, the notification erroneously requested to increase expenditure authority in Items 4265-001-0890 and 4265-111-0890. This notification serves as a revised request and correctly identifies the items to be adjusted.

This request meets the following criteria, as required in subdivision (b) of Section 28.00:

- The funds will be expended for enhancing genome sequencing and bioinformatics capacity within statewide, local, and territorial health agencies which is consistent with state law.

- The funds are made available to the state under conditions permitting their use only for the specified purpose, and the additional expenditure proposed would apply to this specified funding purpose.
- Acceptance of the additional funding does not impose on the state any requirement to commit or expend new state funds for any program or purpose.
- The need exists to expend the additional funding during the current fiscal year because of ongoing COVID-19 emergency response.

Finance concurs with the necessity of this change to the approved budget and requests a waiver of the 30-day review period from the above date so that DPH may fully encumber the funds in the current year, consistent with the original notification to the Joint Legislative Budget Committee.

If you have any questions or need additional information regarding this matter, please call Sonal Patel, Principal Program Budget Analyst, at (916) 445-6423.

KEELY MARTIN BOSLER
Director

By:

A handwritten signature in black ink, appearing to read "Erika Li". The signature is written in a cursive, flowing style.

ERIKA LI
Chief Deputy Director

Attachment

cc: On following page

cc: Honorable Dr. Joaquin Arambula, Chair, Assembly Budget Subcommittee No. 1
Honorable Susan Talamantes Eggman, Chair, Senate Budget and Fiscal Review
Subcommittee No. 3
Honorable Jim Nielsen, Vice Chair, Senate Budget and Fiscal Review Committee
Honorable Vince Fong, Vice Chair, Assembly Budget Committee
Gabriel Petek, Legislative Analyst (3)
Elisa Wynne, Staff Director, Senate Budget and Fiscal Review Committee
Kirk Feely, Fiscal Director, Senate Republican Fiscal Office
Christopher W. Woods, Senate President pro Tempore's Office (2)
Christian Griffith, Chief Consultant, Assembly Budget Committee
Joseph Shinstock, Fiscal Director, Assembly Republican Caucus, Office of Policy
and Budget
Paul Dress, Caucus Co-Chief of Staff, Assembly Republican Leader's Office
Katja Townsend, Capitol Director, Assembly Republican Leader's Office
Jason Sisney, Assembly Speaker's Office (2)
Mark McKenzie, Staff Director, Senate Appropriations Committee
Jay Dickenson, Chief Consultant, Assembly Appropriations Committee
Mark Ghaly, Secretary, California Health and Human Services Agency
Marko Mijic, Undersecretary, California Health and Human Services Agency
Brendan McCarthy, Deputy Secretary of Program and Fiscal Affairs, California
Health and Human Services Agency
Julie Souliere, Assistant Secretary, California Health and Human Services Agency
Tomás J. Aragón, State Public Health Officer, Director of California Department of
Public Health
Brandon Nunes, Chief Deputy Director of Operations, California Department of
Public Health
Susan Fanelli, Chief Deputy Director of Policy and Programs, California Department
of Public Health
Phuong La, Deputy Director, Financial Management Branch, California Department
of Public Health

Please report dollars in thousands.

DEPARTMENT California Department of Public Health (CDPH)	ITEM NO./ FISCAL YEAR 2021-22	NOTIFICATION LETTER TO LEGISLATURE: <input type="checkbox"/> 30-DAY NOTICE <input checked="" type="checkbox"/> REQUEST WAIVER OF 30-DAY NOTICE
--	---	--

PROGRAM TITLE PER GOVERNOR'S BUDGET:

Public & Environmental Health

FUNDING (SPECIFY FUND)	CURRENTLY BUDGETED	REQUESTED CHANGE (+) OR (-)	TOTAL
4265-001-0001	178,884	0	178,884
4265-111-0001	204,196	0	204,196

(Check appropriate boxes)

- The funds will be expended for a purpose that is consistent with state law (explain use of funds in Part A below).
- The funds are made available to the state under conditions permitting their use only for a specified purpose, and the additional expenditure proposed under this section would apply to that specified funding purpose (as supported by explanation for the purpose of the funds).
- Acceptance of additional funding does not impose on the state any requirement to commit or expend new state funds for any program or purpose.
- The need exists to expend the additional funding during the current fiscal year (explain in Part B below).
- This application is provided to Finance within 45-days of official notice of receipt of funds.
- Explanation of delayed notification to Finance is attached (required if 45-day notification period is exceeded).
- A copy of the official notice of fund availability is attached to this application.
- One-time expenditure.
- Ongoing commitment from this source (if checked, explain under Program Proposal).
- Matching funds required (if checked, explain under Program Proposal).
- Expenditure either supplements or supplants an existing state-funded program (if checked, explain under Program Proposal).

PART A: For what purpose will the funds be expended?

THE FUNDING WILL BE USED TO ENHANCE SEQUENCING AND BIOINFORMATICS CAPACITY IN STATE, LOCAL, AND TERRITORIAL HEALTH AGENCIES. TO DO THIS , CDPH PLANS TO HIRE 4 MICROBIOLOGISTS TO INCREASE LABORATORY SEQUENCING AND BIOINFORMATICS CAPABILITIES, HIRE 1 LAB TECHNICIAN TO SUPPORT LABORATORY SEQUENCING, AND CONTRACT WITH UNIVERSITY OF CALIFORNIA RESEARCH LABORATORIES FOR SARS-COV-2 SEQUENCING FOR STATE AND LOCAL HEALTH JURISDICTIONS. CDPH WILL PURCHASE EQUIPMENT AND SUPPLIES TO MAINTAIN AND EXPAND TERRA-GCP CLOUD BIOINFORMATICS SERVICES FOR SARS-COV-2 AND OTHER PATHOGENS AND WILL ALSO PROVIDE STATE AND LOCAL PUBLIC HEALTH LABORATORY AND EPIDEMIOLOGIST ACCESS TO CLOUD BIOINFORMATICS SERVICES AND DASHBOARDS. CDPH WILL CONTRACT WITH UC SANTA CRUZ FOR INTEGRATION OF GENOMIC AND EPIDEMIOLOGIC DATA AND DEVELOP WGS PIPELINES THAT INTEGRATE WITH EPIDEMIOLOGIC DATADATA INTEGRATION

PART B: Explain the need to expend the funds in the current fiscal year, including the consequence of waiting until budget year to expend the funds:

THE FUNDING WAS AWARDED IN THE CURRENT FISCAL YEAR AND ARE INTENDED TO BE USED IMMEDIATELY IN THE RESPONSE TO THE COVID-19 PANDEMIC.

PROGRAM PROPOSAL (Attach additional information as necessary)

TITLE:

STATUTORY AUTHORITY: (state, federal, as appropriate)

DESCRIPTION:

SEE ATTACHED WORKPLANS AND BUDGETS ASSOCIATED WITH THIS FUNDING.

JUSTIFICATION:

THE RAPID EMERGENCE AND GLOBAL SPREAD OF SARS-COV-2, THE PATHOGEN THAT CAUSES COVID-19, HIGHLIGHTS THE THREAT POSED BY NOVEL PATHOGENS. ONE OF THE MOST VERSATILE TOOLS IN UNDERSTANDING AND GUIDING THE RESPONSE TO THESE EMERGENCES IS GENOMIC SEQUENCING. WHILE THE ABILITY TO DECODE MICROBIAL GENOMES HAS EXISTED SINCE THE 1970S, THE ADVENT OF HIGH-THROUGHPUT DNA SEQUENCING, ALSO CALLED NEXT-GENERATION SEQUENCING, HAS GREATLY EXPANDED THE USE OF THESE TECHNOLOGIES IN PUBLIC HEALTH.

THE ADVANCED MOLECULAR DETECTION (AMD) PROGRAM IS DEVELOPING APPLICATIONS TO PROTECT AMERICA'S HEALTH AND BUILDING CAPACITY IN NATIONAL, STATE AND LOCAL PUBLIC HEALTH LABORATORIES. MODERNIZING INFECTIOUS DISEASE LABORATORIES, TRAINING STAFF, AND EXPANDING THE APPLICATION OF THESE NEW TECHNOLOGIES WILL ENSURE THAT AMERICANS HAVE THE STRONGEST PROTECTION AGAINST INFECTIOUS DISEASE THREATS. THE PURPOSE OF THIS ANNOUNCEMENT IS TO SUPPORT SEQUENCING AND ANALYTIC CAPACITY BUILDING IN MICROBIAL GENOMICS AND BIOINFORMATICS AS WELL AS TO FURTHER THE DEVELOPMENT OF AMD CAPACITY IN HEALTH DEPARTMENTS.

IN ORDER FOR PATHOGEN GENOMIC SEQUENCE DATA TO MOST EFFECTIVELY IMPACT PUBLIC HEALTH, THE DATA NEED TO BE INTEGRATED WITH THEIR CORRESPONDING EPIDEMIOLOGIC OR CLINICAL DATA, ANALYZED TOGETHER, AND INTERPRETED. WHILE THE AMD PROGRAM HAS ALWAYS SUPPORTED ACTIVITIES THAT FURTHER THIS OBJECTIVE, WITH THE FUNDING DESCRIBED HERE, THE PROGRAM INTENDS TO ACCELERATE PROGRESS BY ENABLING STATE, TERRITORIAL AND LOCAL HEALTH DEPARTMENTS TO MAKE THE LONG-TERM INVESTMENTS IN WORKFORCE AND/OR INFRASTRUCTURE THAT ARE NECESSARY TO ACHIEVE IT.

SUBMITTED BY:

BUDGET OFFICER:

DATE:

5/5/2022

APPROVED BY DEPARTMENT OF FINANCE:

DATE SUBMITTED TO LEGISLATURE:

05/27/2022

DIRECTOR:

DATE:

05/05/22

PPBA:

Sonal D. Patel

DATE:

05/24/2022



December 21, 2021

Honorable Nancy Skinner, Chair
Joint Legislative Budget Committee
Senate Budget and Fiscal Review Committee

Honorable Phil Ting, Chair
Assembly Budget Committee

Honorable Anthony Portantino, Chair
Senate Appropriations Committee

Honorable Lorena Gonzalez, Chair
Assembly Appropriations Committee

Department of Public Health—Office of Emergency Preparedness, Budget Increase for Fiscal Year 2021-22

Pursuant to Provision 4 of Item 4265-001-0890 in the 2021 Budget Act, the following report is respectfully submitted.

The Department of Public Health respectfully requests approval of a current year budget revision in the 2021 Budget Act to increase expenditure authority in accordance with a notice of award in the amount of \$19.6 million, which was received from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention on May 12, 2021. Of the total amount, \$17,877,000 is for state operations and \$1,710,000 for local assistance.

This funding will provide the Department of Public Health with support for genome sequencing and surveillance. The delay in submission of this letter is due to the increased workload pressures and redirection of staff resources toward the COVID-19 pandemic response.

Finance concurs with the necessity of this change to the approved budget.

If you have any questions or need additional information regarding this matter, please call Jack Zwald, Principal Program Budget Analyst, at (916) 445-6423.

KEELY MARTIN BOSLER
Director
By:

ERIKA LI
Chief Deputy Director

cc: On following page

CC: Honorable Dr. Joaquin Arambula, Chair, Assembly Budget Subcommittee No. 1
Honorable Susan Talamantes Eggman, Chair, Senate Budget and Fiscal Review
Subcommittee No. 3
Honorable Jim Nielsen, Vice Chair, Senate Budget and Fiscal Review Committee
Honorable Vince Fong, Vice Chair, Assembly Budget Committee
Gabriel Petek, Legislative Analyst (3)
Joe Stephenshaw, Staff Director, Senate Budget and Fiscal Review Committee
Kirk Feely, Fiscal Director, Senate Republican Fiscal Office
Christopher W. Woods, Senate President pro Tempore's Office (2)
Christian Griffith, Chief Consultant, Assembly Budget Committee
Joseph Shinstock, Fiscal Director, Assembly Republican Caucus, Office of Policy and
Budget
Paul Dress, Caucus Co-Chief of Staff, Assembly Republican Leader's Office
Luigi Luciano, Legislative Director, Assembly Republican Leader's Office
Jason Sisney, Assembly Speaker's Office (2)
Mark McKenzie, Staff Director, Senate Appropriations Committee
Jay Dickenson, Chief Consultant, Assembly Appropriations Committee
Tomás Aragón, Director, Department of Public Health



Recipient Information

1. Recipient Name

Public Health Foundation Enterprises, Inc.
13300 Crossroads Pkwy STE 450
Suite 450
City Of Industry, CA 91746-3405
[NO DATA]

2. Congressional District of Recipient

32

3. Payment System Identifier (ID)

1952557063A1

4. Employer Identification Number (EIN)

952557063

5. Data Universal Numbering System (DUNS)

082199324

6. Recipient's Unique Entity Identifier

7. Project Director or Principal Investigator

Dr. James Watt M.D., M.P.H.
Division Chief
James.Watt@cdph.ca.gov
510-620-3727

8. Authorized Official

Mr. Peter Dale
Director, Contract and Grants Management
PHFEContracts@phfe.org
(562) 222-7886

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Kim McDowell
Grant Management Specialist
qpx9@cdc.gov
404-498-4105

10. Program Official Contact Information

Mrs. Janice Downing
Public Health Analyst
jsb3@cdc.gov
404-639-7808

Federal Award Information

11. Award Number

6 NU50CK000539-02-11

12. Unique Federal Award Identification Number (FAIN)

NU50CK000539

13. Statutory Authority

301(A)AND317(K)(2)PHS42USC241(A)247B(K)2

14. Federal Award Project Title

PHFE CDPH ELC 2019-2024

15. Assistance Listing Number

93.323

16. Assistance Listing Program Title

Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)

17. Award Action Type

Supplement

18. Is the Award R&D?

No

Summary Federal Award Financial Information

19. Budget Period Start Date	08/01/2020	- End Date	07/31/2021
20. Total Amount of Federal Funds Obligated by this Action			\$19,586,558.00
20a. Direct Cost Amount			\$19,586,558.00
20b. Indirect Cost Amount			\$0.00
21. Authorized Carryover			\$0.00
22. Offset			\$0.00
23. Total Amount of Federal Funds Obligated this budget period			\$2,604,432,736.00
24. Total Approved Cost Sharing or Matching, where applicable			\$0.00
25. Total Federal and Non-Federal Approved this Budget Period			\$2,624,019,294.00
26. Project Period Start Date	08/01/2019	- End Date	07/31/2024
27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period			Not Available

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Ms. Freda Johnson
Grants Management Officer

30. Remarks



Recipient Information
Recipient Name Public Health Foundation Enterprises, Inc. 13300 Crossroads Pkwy STE 450 Suite 450 City Of Industry, CA 91746-3405 [NO DATA]
Congressional District of Recipient 32
Payment Account Number and Type 1952557063A1
Employer Identification Number (EIN) Data 952557063
Universal Numbering System (DUNS) 082199324
Recipient's Unique Entity Identifier Not Available
31. Assistance Type Cooperative Agreement
32. Type of Award Demonstration

33. Approved Budget (Excludes Direct Assistance)	
I. Financial Assistance from the Federal Awarding Agency Only	
II. Total project costs including grant funds and all other financial participation	
a. Salaries and Wages	\$47,546,785.00
b. Fringe Benefits	\$15,666,717.00
c. Total Personnel Costs	\$63,213,502.00
d. Equipment	\$1,466,873.00
e. Supplies	\$1,801,084.00
f. Travel	\$354,420.00
g. Construction	\$0.00
h. Other	\$932,576,174.00
i. Contractual	\$1,616,737,579.00
j. TOTAL DIRECT COSTS	\$2,616,149,632.00
k. INDIRECT COSTS	\$7,869,662.00
l. TOTAL APPROVED BUDGET	\$2,624,019,294.00
m. Federal Share	\$2,624,019,294.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes						
FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION	
1-9390GF6	19NU50CK000539PHL2C4	CK	41.51	\$1,994,622.00	75-X-0140	
1-9390GR3	19NU50CK000539BDC5	CK	41.51	\$500,000.00	75-2124-0943	
1-9390H08	19NU50CK000539AMD2C6	CK	41.51	\$17,091,936.00	75-X-0943	



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NU50CK000539-02-11

FAIN# NU50CK000539

Federal Award Date: 05/12/2021

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

Public Health Foundation Enterprises, Inc.

6 NU50CK000539-02-11

1. Revised Terms and Conditions - Supp Funding

ADDITIONAL AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CK19-1904, entitled *Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases(ELC)*, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NOA).

Supplemental Component Funding: Additional funding in the amount \$19,586,558 is approved for the Year 02 budget period, which is August 1, 2020 through July 31, 2021, this award. The availability of funds is shown below.

COVID Funded Component	Amount	End of Funding Availability	Document Number in PMS
Project E: AMD Sequencing & Analytics	\$17,091,936	July 31, 2024	AMD2C6
Strengthening PHL Preparedness	\$1,994,622	July 31, 2022	PHL2C4
Border Region Partnerships	\$500,000	July 31, 2022	BDXC5

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139); the Consolidated Appropriations Act and the Coronavirus Response and Relief Supplement Appropriations Act, 2021 (P.L. 116-260) and/or the American Rescue Plan of 2021 [P.L. 117-2] agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting guidance is posted at: <https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf>.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC

copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

To achieve the public health objectives of ensuring the health, safety, and welfare of all Americans, Recipient must distribute or administer vaccine without discriminating on non-public-health grounds within a prioritized group.

Unallowable Costs:

1. Research
2. Clinical care
3. Publicity and propaganda (lobbying):
4. Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - a. publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - b. the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body o See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:
https://www.cdc.gov/grants/documents/AntiLobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
5. All unallowable costs cited in CDC-RFA-CK19-1904 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

COVID-19 Funding Budget Revision Requirement: The recipient must submit a revised budget with a narrative justification within 90 days of receipt of the Notice of Award. If the date falls on a weekend or holiday, the submission will be due the following business day. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the Awarding Agency Contact Information section on the first page before the due date.

REPORTING REQUIREMENTS

The following is a summary of the reporting requirements for the *AMD Sequencing & Analytics*.

1. Within five (5) business days of receipt of this guidance, the Authorized Official is required to acknowledge receipt of this guidance by submitting a Grant Note in GrantSolutions.
2. Quarterly progress reports on milestones in approved workplans via REDCap.

3. Monthly fiscal reports (beginning 30 days after NOAs are issued).
4. Performance measure data.
5. CDC may require recipients to develop annual progress reports (APRs). CDC will provide APR guidance and optional templates should they be required.

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIS):

Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Kim McDowell, Grants Management Specialist
Centers for Disease Control and Prevention
Branch 1
2939 Flowers Road, MS-TV-2 Atlanta, GA 30341
Email: gpx9@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator 3301 Independence Avenue, SW
Cohen Building, Room 5527 Washington, DC 20201
Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or Email:
MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1- 800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health

and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of **Page 2** of the Notice of Award must be known to draw down funds.

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

Public Health Foundation Enterprises
 AMD Sequencing and Analytics 3608
 0187.3608
 5/12/2021 - 7/31/2024
 CFDA #:

Position Count	Expenditure Type	Employee Name	(if available) Monthly Salary/Hourly Range (per budget)	Salary/Hourly Rate	Total % Budgeted	Months Position Budgeted	Original Budget
1	SW-COVIDNet WGS Scientist	Vacant	\$ 8,283.87	-	1.00	36	298,219.29
2	SW-COVIDNet WGS Scientist	Vacant	\$ 8,283.87	-	1.00	36	298,219.29
3	SW-COVIDNet WGS Scientist	Vacant	\$ 8,283.87	-	1.00	36	298,219.29
4	SW-COVIDNet WGS Scientist	Vacant	\$ 8,283.87	-	1.00	36	298,219.29
5	SW-COVIDNet WGS Lab Technician	Vacant	\$ 6,029.10	-	1.00	36	217,047.42
Total Salaries and Wages							\$ 1,409,924.58
FB - Accrued Vacation Expense					3.87%		\$ 54,564.08
FB - Accrued Vac. Fringe @ 27.50%					1.06%		\$ 15,005.12
FB - Fringe Benefits @ 27.50% FT & 12.4% PT					27.50%		\$ 387,729.26
Total Fringe Benefits					32.43%		\$ 457,298.46
Total Personnel							\$ 1,867,223.04
Consortium/Contractual Cost							
CC - SubR							\$ 25,000.00
CC - SubR>\$25K							\$ 15,010,490.65
CDPH Lab Cost - Facilities							\$ 205,000.00
State Lab Cost- IT Bundle- \$10,000/FTE							\$ 50,000.00
UCSF #1 (Chow) - UC academic lab sequencing partnership							\$ 1,500,000.00
UCSF #2 (Chiu) - UC academic lab sequencing partnership							\$ 1,500,000.00
UCLA #1 (Li) - UC academic lab sequencing partnership							\$ 1,500,000.00
UCLA #2 (Eskin) - UC academic lab sequencing partnership							\$ 1,330,490.65
UCSD (Laurent) - UC academic lab sequencing partnership							\$ 1,500,000.00
UCSB (Arias) - UC academic lab sequencing partnership							\$ 900,000.00
UCI (Sondmeyer) : UC academic lab sequencing partnership							\$ 900,000.00
UCB #1 (Wyman): UC academic lab sequencing partnership							\$ 900,000.00
UCB #2 (Nelson): UC academic lab sequencing partnership							\$ 900,000.00
Let's Get Checked or equivalent: Private lab sequencing partnership							\$ 900,000.00
Theiagen - Terra-GCP WGS analysis platform & workflows: Maintain and expand cloud bioinformatics services for SARS-C							\$ 1,950,000.00
Taborda or equivalent - GCP user authentication: Provide state and local Public Health Laboratory and epidemiologist acc							\$ 1,000,000.00
Total Consortium/Contractual Cost							\$ 15,035,490.65
Total Direct Cost							\$ 16,902,713.69
FA - Indirect							
10.00% MTDC							\$ 189,222.30
							\$ 189,222.30
Total Budget							\$ 17,091,936.00

posal/Approval Budget	\$ 17,091,936.00
Carryforward	
Difference	\$ 0.00

Public Health Foundation Enterprises
Strengthening PHL Preparedness 3708
0187.3708
5/1/2021-7/31/2022
CFDA #:

Position Count	Expenditure Type	Employee Name	(if available) Monthly Salary/Hourly Range (per budget)	Salary/Hourly Rate	Total % Budgeted	Months Position Budgeted	Original Budget
Consortium/Contractual Cost							
	CC - SubR						\$ 25,000.00
	CC - SubR>\$25K						\$ 1,967,122.60
	<i>Next Generation sequencing (NGS) technologies, reagents, & supplies</i>						\$ 142,473.00
	<i>Lab Supplies - MDL</i>						\$ 59,973.00
	<i>Electronic monitoring system for temperature-controlled storage and incubator units (MDL)</i>						\$ 14,000.00
	<i>Refrigerators and freezers for storage of LRN-B reagents and specimens (MDL)</i>						\$ 46,000.00
	<i>PCR enclosure for testing and assay development (MDL)</i>						\$ 5,000.00
	<i>Shipping supplies and services for suspect biothreats</i>						\$ 15,000.00
	<i>12 local LRN-B Reference labs at \$142,473 each</i>						\$ 1,709,676.60
	Total Consortium/Contractual Cost						\$ 1,992,122.00
Total Direct Cost							\$ 1,992,122.00
	FA - Indirect		10.00% MTDC				\$ 2,500.00
							\$ 2,500.00
Total Budget							\$ 1,994,622.00

Proposal/Approval Budget \$ 1,994,622.00
Carryforward
Difference \$ 3:27 PM 5/3/2022 -

Public Health Foundation Enterprises
 Border Region Partnerships 3808
 0187.3808
 5/1/2021-7/31/2022
 CFDA #:

Position Count	Expenditure Type	Employee Name	(if available) Monthly Salary/Hourly Range (per budget)	Salary/Hourly Rate	Total % Budgeted	Months Position Budgeted	Original Budget
Supplies							
	SP - Personal Protective Gear						\$ 38,181.82
	SP - Educational Material						\$ 30,327.82
	Total Supplies						\$ 68,509.64
Equipment							
	Equipment - Mobile Van (2)						\$ 400,000.00
	Total Equipment						\$ 400,000.00
Travel							
	TC - Mileage						\$ 20,000.00
	Total Travel						\$ 20,000.00
Other Costs							
	OC - Medical Van Storage						\$ 2,400.00
	Total Other Costs						\$ 2,400.00
Total Direct Cost							\$ 490,909.64
	FA - Indirect						\$ 9,090.36
							\$ 9,090.36
	Total Budget						\$ 500,000.00

Proposal/Approval Budget \$ 500,000.00
 Carryforward
 Difference \$ 0.00